Cas:475193-31-8 2-Methylthioadenosine diphosphate trisodium manufacturer & supplier

Chemical Name:2-Methylthioadenosine diphosphate trisodium

CAS.NO:475193-31-8

Synonyms:Trisodium 2-(methylsulfanyl)-5′-O-[(phosphonatooxy)phosphinato]ad enosine

Molecular Formula:C₁₁H₁₄N₅Na₃O₁₀P₂S

Molecular Weight:539.23800

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:286.01000

Exact Mass:538.96300

LogP:0.87170

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Trisodium 2-(methylsulfanyl)-5′-O-[(phosphonatooxy)phosphinato]ad enosine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Trisodium 2-(methylsulfanyl)-5′-O-[(phosphonatooxy)phosphinato]ad enosine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Trisodium 2-(methylsulfanyl)-5′-O-[(phosphonatooxy)phosphinato]ad enosine Use and application,Trisodium 2-(methylsulfanyl)-5′-O-[(phosphonatooxy)phosphinato]ad enosine technical grade,usp/ep/jp grade.

Related News: Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma. 2-Methylthioadenosine diphosphate trisodium manufacturer Travel alerts: As the Wuhan coronavirus spreads around China, infecting more people, a number of countries have raised their travel advisory warnings. 2-Methylthioadenosine diphosphate trisodium supplier Travel alerts: As the Wuhan coronavirus spreads around China, infecting more people, a number of countries have raised their travel advisory warnings. 2-Methylthioadenosine diphosphate trisodium vendor Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma. 2-Methylthioadenosine diphosphate trisodium factory The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful.